CSF Protein Markers As Prognostic Indicators of the Response to CSF Shunt in Normotensive Hydrocephalus

Launched by UNIVERSITY OF VALENCIA · Jun 13, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how certain proteins in the cerebrospinal fluid (the fluid surrounding the brain and spinal cord) can help predict how well patients will respond to a treatment called a shunt, which helps to drain excess fluid in people with a condition known as chronic adult hydrocephalus. Researchers are particularly looking at proteins called Amyloid Beta 1-42, H-tau, and Phospho-tau, as well as their relationship to cognitive and motor skills after the treatment. The goal is to identify which patients are likely to benefit from the shunt and which ones may not see much improvement.

If you are at least 18 years old and have been diagnosed with chronic adult hydrocephalus, you may be eligible to participate in this trial. However, patients with other types of dementia or certain brain diseases will not be included. Participants can expect to undergo tests to measure their cerebrospinal fluid and cognitive abilities, and they will be monitored to see how their condition evolves after receiving the shunt. This trial is currently recruiting participants, and your involvement could help improve understanding of this condition and lead to better treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Minimum age of 18 years, there is no maximum age, especially if it is understood that this pathology is more frequent as one advance in age, especially among males; pathology compatible with chronic adult hydrocephalus
• Exclusion Criteria:
• • All patients whose suspected diagnosis is not adult chronic hydrocephalus will be excluded, specifically those with cerebrovascular disease, dementia not due to adult chronic hydrocephalus, Alzheimer's disease, Parkinson's disease, and hereditary degenerative brain pathology. Huntington's chorea